Expert Interview
Third View: Discussing the standard of care and the recent label expansion of Prevymis by Merck Pharmaceuticals for CMV prophylaxis after kidney transplant in Donor CMV-seropositive/Recipient CMV-seronegative patients.
Ticker(s): MRKInstitution: SWPNA
- Manages over 80 patients for IgAN currently
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
